SynCardia Systems, LLC, headquartered in Tucson, Arizona, was founded in 2001 and is the sole manufacturer and provider of the world's only clinically proven and commercially approved Total Artificial Heart.[1]
SynCardia was founded in 2001 by cardiothoracic surgeon Jack G. Copeland, MD; biomedical engineer Richard G. Smith, MSEE, CCE; and interventional cardiologist Marvin J. Slepian, MD; with Steven Langford BSEE, as General Manager. Today, SynCardia is a wholly owned subsidiary of Picard Medical and remains the sole manufacturer and provider of the world’s only commercially approved Total Artificial Heart. In clinical use for more than 35 years, the SynCardia temporary Total Artificial Heart (TAH-t) is the most widely used and extensively studied Total Artificial Heart in the world.
In 2004, the FDA approved the SynCardia TAH (formerly known as the "CardioWest temporary Total Artificial Heart”) as a bridge to donor heart transplant[1] in cardiac transplant-eligible candidates at risk of imminent death from end-stage biventricular failure.[3]
SynCardia's products include the original 70cc TAH; the newer, smaller 50cc TAH, designed to fit patients of smaller stature, including more women and adolescents; the Companion 2 (C2) Hospital Driver, which provides pneumatic power to the TAH from implant through patient recovery in the hospital; and the Freedom Portable Driver, a smaller, portable pneumatic pump for the TAH that allows stable patients who meet discharge criteria to enjoy life at home while they wait for a matching donor heart.[2]
In addition to its being used as a bridge to transplant in the U.S., Canada and Europe, the 70cc TAH has supported several patients as a destination therapy in adult patients who are not eligible for transplant. The longest patient supported by the SynCardia Total Artificial Heart on a person who became not eligible for transplant was over 6 years and 9 months. He lived a near normal lifestyle at home with his wife. The smaller 50cc TAH is currently approved for use as a bridge to transplant for both pediatric and adult patients.[2]
In September 2016, SynCardia was acquired by Versa Capital Management, LLC, a Philadelphia-based private equity investment firm and then was acquired by Piccard Medical in September 2021, which has provided additional financial and operational resources.[4]
A documentary about the SynCardia TAH was released in 2016.[5] Patrick Schnegelsberg was named CEO of SynCardia.[6]
^ abMcKellar, Shelley (2018). Artificial Hearts: The Allure and Ambivalence of a Controversial Medical Technology. Johns Hopkins University. p. 315. ISBN978-1421423555.
^ abc"About SynCardia". SynCardia. Retrieved 6 November 2019.
^Elliott, Tonya; Sweet, Leslie C.; Wolfe, Alan C. (2018). "21. Mechanical circulatory support devices in transport". In Holleran, Reneé Semonin; Wolfe, Allen C.; Frakes, Michael A. (eds.). Patient Transport: Principles and Practice. Missouri: Elsevier. p. 337. ISBN978-0-323-40110-4.
^Chakraborthy, Srijanee (20 September 2016). "Versa Capital Management acquires medical technology firm SynCardia". Verdict Medical Devices. Retrieved 26 January 2019.
^"New Documentary Traces History of SynCardia Total Artificial Heart". DAIC. 24 March 2016. Retrieved 26 January 2019.
^"SynCardia Welcomes New CEO". Medical Product Outsourcing. Retrieved 6 November 2019.
External linksedit
Company website
February 23, 2024
syncardia, systems, headquartered, tucson, arizona, founded, 2001, sole, manufacturer, provider, world, only, clinically, proven, commercially, approved, total, artificial, heart, llcformerlycardiowestcompany, typeprivate, subsidiary, picard, medical, companyi. SynCardia Systems LLC headquartered in Tucson Arizona was founded in 2001 and is the sole manufacturer and provider of the world s only clinically proven and commercially approved Total Artificial Heart 1 SynCardia Systems LLCFormerlyCardioWestCompany typePrivate Subsidiary of Picard Medical CompanyIndustryCardiac Medical DevicesFounded2001HeadquartersTucson Arizona USAKey peoplePatrick Schnegelsberg CEOProductsArtificial heartsNumber of employees 80Websitesyncardia wbr comThe SynCardia temporary Total Artificial Heart TAH has been in clinical use for more than 35 years 2 Contents 1 History 2 See also 3 References 4 External linksHistory editSynCardia was founded in 2001 by cardiothoracic surgeon Jack G Copeland MD biomedical engineer Richard G Smith MSEE CCE and interventional cardiologist Marvin J Slepian MD with Steven Langford BSEE as General Manager Today SynCardia is a wholly owned subsidiary of Picard Medical and remains the sole manufacturer and provider of the world s only commercially approved Total Artificial Heart In clinical use for more than 35 years the SynCardia temporary Total Artificial Heart TAH t is the most widely used and extensively studied Total Artificial Heart in the world In 2004 the FDA approved the SynCardia TAH formerly known as the CardioWest temporary Total Artificial Heart as a bridge to donor heart transplant 1 in cardiac transplant eligible candidates at risk of imminent death from end stage biventricular failure 3 SynCardia s products include the original 70cc TAH the newer smaller 50cc TAH designed to fit patients of smaller stature including more women and adolescents the Companion 2 C2 Hospital Driver which provides pneumatic power to the TAH from implant through patient recovery in the hospital and the Freedom Portable Driver a smaller portable pneumatic pump for the TAH that allows stable patients who meet discharge criteria to enjoy life at home while they wait for a matching donor heart 2 In addition to its being used as a bridge to transplant in the U S Canada and Europe the 70cc TAH has supported several patients as a destination therapy in adult patients who are not eligible for transplant The longest patient supported by the SynCardia Total Artificial Heart on a person who became not eligible for transplant was over 6 years and 9 months He lived a near normal lifestyle at home with his wife The smaller 50cc TAH is currently approved for use as a bridge to transplant for both pediatric and adult patients 2 In September 2016 SynCardia was acquired by Versa Capital Management LLC a Philadelphia based private equity investment firm and then was acquired by Piccard Medical in September 2021 which has provided additional financial and operational resources 4 A documentary about the SynCardia TAH was released in 2016 5 Patrick Schnegelsberg was named CEO of SynCardia 6 See also editArtificial heart Artificial heart valve Wayne Griffin Jack G CopelandReferences edit a b McKellar Shelley 2018 Artificial Hearts The Allure and Ambivalence of a Controversial Medical Technology Johns Hopkins University p 315 ISBN 978 1421423555 a b c About SynCardia SynCardia Retrieved 6 November 2019 Elliott Tonya Sweet Leslie C Wolfe Alan C 2018 21 Mechanical circulatory support devices in transport In Holleran Renee Semonin Wolfe Allen C Frakes Michael A eds Patient Transport Principles and Practice Missouri Elsevier p 337 ISBN 978 0 323 40110 4 Chakraborthy Srijanee 20 September 2016 Versa Capital Management acquires medical technology firm SynCardia Verdict Medical Devices Retrieved 26 January 2019 New Documentary Traces History of SynCardia Total Artificial Heart DAIC 24 March 2016 Retrieved 26 January 2019 SynCardia Welcomes New CEO Medical Product Outsourcing Retrieved 6 November 2019 External links editCompany website Retrieved from https en wikipedia org w index php title SynCardia Systems amp oldid 1186089853, wikipedia, wiki, book, books, library,
